A novel cell-penetrating peptide restored fat tissue function and prevented cancer-related wasting in mice without affecting tumor growth or causing side effects.
First-in-classPen-X-ACIP is the first peptide drug designed to stabilize AMPK in fat tissue to prevent cancer cachexia — a condition with zero approved treatments
What the researchers found
Researchers developed a novel peptide called Pen-X-ACIP that stabilizes the AMPK enzyme complex in fat tissue — a process that breaks down during cancer cachexia. When injected into tumor-bearing mice, the peptide prevented cachexia progression, preserved body weight and fat tissue mass, and did not affect tumor growth or cause side effects in other organs. The peptide was efficiently taken up by fat cells, inhibited the excessive fat breakdown (lipolysis) that drives wasting, and restored AMPK signaling. It also worked in human fat cells in the lab, providing a proof of concept for a first-in-class therapy.
Why it matters
Cancer cachexia — the severe muscle and fat wasting that affects up to 80% of advanced cancer patients — has no approved treatment. This study identifies a specific molecular target (AMPK destabilization in fat tissue) and delivers a peptide drug that addresses it. By using a cell-penetrating peptide to get the drug inside fat cells, the researchers created a potentially targeted approach that doesn't interfere with cancer treatment.
The numbers in context
Pen-X-ACIP prevented cachexia progression · Preserved body weight and adipose tissue mass · No side effects in peripheral organs · No effect on tumor growth · Effective in human adipocytes in vitro
How the study worked
The team designed a peptide (ACIP) that stabilizes the AMPK complex, fused it to the cell-penetrating peptide penetratin via a chemical linker, and tested it in cell cultures and tumor-bearing mice. They measured fat cell uptake, lipolysis inhibition, AMPK signaling restoration, tissue distribution after injection, body weight, fat mass, and tumor growth. They also tested the peptide's activity in human fat cells.
Who was studied
Tumor-bearing mice (in vivo) and human adipocytes (in vitro)
What this study cannot tell us
This is preclinical proof-of-concept work in mice — no human trials have been conducted. The abstract does not report specific quantitative results (exact weight preservation numbers, sample sizes). Long-term safety and efficacy data are not available. The peptide requires injection (intraperitoneal), and it's unknown if other delivery routes would work. Whether results in mouse cachexia models translate to the complex presentation of human cancer cachexia remains to be determined.
How to read the evidence
This is a preclinical study published in Molecular Therapy, a respected gene/cell therapy journal. It demonstrates proof of concept in animal models with supporting human cell data, but no clinical trials have been conducted. The evidence is moderate — strong for preclinical, but unproven in humans.
When this study was published
Published in 2023, this is recent preclinical research. Clinical development timelines typically require 5-10 years from this stage, so a human-ready drug is likely years away.
The bigger picture
Cancer cachexia affects up to 80% of patients with advanced cancer and is responsible for roughly 20% of cancer deaths, yet there is no FDA-approved treatment. This peptide represents a fundamentally new approach — rather than trying to stimulate appetite or block inflammation, it targets the specific molecular breakdown (AMPK destabilization) that causes fat tissue to malfunction during cachexia. The use of a cell-penetrating peptide to deliver the therapy directly into fat cells is also a notable advance in peptide drug design.
Questions still open
- Will this peptide be effective in human cancer cachexia patients where the condition is more complex than in mouse models?
- Can the peptide be modified for subcutaneous injection or other more practical delivery routes for patients?
- Would combining this AMPK-stabilizing peptide with appetite-stimulating drugs provide greater benefit against cachexia?
Common questions
What is cancer cachexia and why is it so dangerous?
How does this peptide drug work differently from other approaches?
Read the original research
Development of a peptide drug restoring AMPK and adipose tissue functionality in cancer cachexia.
Molecular therapy : the journal of the American Society of Gene Therapy, 31(8), 2408-2421
Citation
Ji, Honglei; Englmaier, Felix; Morigny, Pauline; Giroud, Maude; Gräsle, Pamina; Brings, Sebastian; Szendrödi, Julia; Berriel Diaz, Mauricio; Plettenburg, Oliver; Herzig, Stephan; Rohm, Maria. (2023). Development of a peptide drug restoring AMPK and adipose tissue functionality in cancer cachexia.. Molecular therapy : the journal of the American Society of Gene Therapy, 31(8), 2408-2421. https://doi.org/10.1016/j.ymthe.2023.06.020